We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+5.13%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.75B
AUM Growth
+$31.3M
Cap. Flow
+$37.1M
Cap. Flow %
2.11%
Top 10 Hldgs %
73.68%
Holding
42
New
–
Increased
21
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$18.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.6M
3
UTHR icon
United Therapeutics
UTHR
+$13.5M
4
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$12.3M
5
SAGE
Sage Therapeutics
SAGE
+$5.08M

Top Sells

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$30.4M
2
ENDP
Endo International plc
ENDP
+$19M
3
RIGL icon
Rigel Pharmaceuticals
RIGL
+$2.89M
4
TLPH icon
Talphera
TLPH
+$1.85M
5
ACGN
Aceragen Inc
ACGN
+$1.13M

Sector Composition

Rank Sector Weight
1 Healthcare 92.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.21M 0.24%
33,214
– –
ALGN icon
27
Align Technology
ALGN
$12.4B
$3.72M 0.21%
38,707
+1,250
+3% +$116K
ALIM
28
DELISTED
Alimera Sciences
ALIM
$3.25M 0.19%
200,920
– –
TLPH icon
29
Talphera
TLPH
$72.7M
$2.69M 0.15%
51,636
-30,094
-37% -$1.85M
CYTK icon
30
Cytokinetics
CYTK
$10.5B
$1.5M 0.09%
123,686
– –
PGEN icon
31
Precigen
PGEN
$2.45B
$1.02M 0.06%
42,277
-5,247
-11% -$146K
CEMP
32
DELISTED
Cempra, Inc.
CEMP
$953K 0.05%
340,320
-2,504,163
-88% -$30.4M
ACGN
33
DELISTED
Aceragen Inc
ACGN
$925K 0.05%
4,537
-4,720
-51% -$1.13M
SPHS
34
DELISTED
Sophiris Bio, Inc.
SPHS
$692K 0.04%
247,000
– –
ARCT icon
35
Arcturus Therapeutics
ARCT
$216M
$573K 0.03%
38,970
– –
OCGN icon
36
Ocugen
OCGN
$475M
$506K 0.03%
5,049
-2,527
-33% -$351K
DRNA
37
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$456K 0.03%
158,279
-109,611
-41% -$390K
ZGNX
38
DELISTED
Zogenix, Inc.
ZGNX
$358K 0.02%
29,500
– –
QURE icon
39
uniQure
QURE
$3.13B
– –
-20,453
Closed -$156K
MRNS
40
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-15,879
Closed -$116K
ENDP
41
DELISTED
Endo International plc
ENDP
– –
-945,330
Closed -$19M
OREX
42
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-167,302
Closed -$555K
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q4 2016 Portfolio in Review

As of Q4 2016, Palo Alto Investors held 42 positions worth $1.75B, up 1.8% from $1.72B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Palo Alto Investors's Q4 2016 filing shows 21 increased, 7 reduced and 4 closed positions. The largest sale was Cempra, Inc., an estimated $30.4M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 95% a quarter earlier.

  • Palo Alto Investors added most to Alexion Pharmaceuticals in Q4 2016, an estimated $18.6M increase.
  • Palo Alto Investors's biggest Q4 2016 reduction was Cempra, Inc., cutting an estimated $30.4M.
  • Palo Alto Investors fully exited Endo International plc in Q4 2016, selling an estimated $19M.
  • Palo Alto Investors's ten largest holdings make up 74% of its $1.75B portfolio in Q4 2016.
  • Palo Alto Investors opened 0 new positions and closed 4 in Q4 2016.
  • Palo Alto Investors's portfolio value rose 1.8% quarter-over-quarter to $1.75B.

Based on Palo Alto Investors's 13F filing for Q4 2016, filed 15 Feb 2017.